SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO), today announced it has appointed Ivan N. Rich, Ph.D., to its advisory board. Dr. Rich’s experience as the founder, chairman and C.E.O. of HemoGenix® Inc., a research laboratory specializing in stem cell applications that serves the biotechnology and pharmaceutical industries, is expected to further enhance ImmuneRegen’s growth as it focuses on research and product development of its drug candidate, the adult stem cell-active compound, Homspera®.
